Chloe Kent
Reporter
Chloe is an award-winning journalist who has specialized in health reporting throughout her career, with a particular focus on women's health and access to medicine. Before joining Generics Bulletin she worked for B2B publishing consortium Verdict, writing about medical technology and pharmaceuticals. Having graduated from the University of York, she went on to train as a journalist with the Press Association.
Latest From Chloe Kent
Advanz Zeroes In On Innovative Assets And M&A
Advanz has identified three key spaces in which it is seeking to generate value: innovative assets, M&A and existing commercial infrastructure.
Sun Pharma Reinforces Position As Indian Industry Leader
Sun Pharmaceuticals continues to dominate the Indian pharmaceutical space while its R&D costs are set to rise.
India Business Makes Gains At Glenmark While Rest Of World Sees Mixed Results
Glenmark’s domestic business was seen to gradually strengthen its market share during Q2, while its North American division saw a minor decline in growth and a drop in COVID-related sales took its toll.
Tough Times Ahead For Towa As Japanese Generics Giant Slashes 2023 Predictions
Towa has made substantial cuts to its 2023 financial guidance as the difficult conditions of the Japanese generics market begin to take their toll.
Beximco Faces Potentially Rough Ride In The Face Of Macroeconomic Headwinds
Following a year of impressive business developments, economic developments such as a depreciating local currency threaten to knock Beximco off-course.
Negotiators Prioritize Generic And Biosimilar Oncology Medicines Over Newer Drugs
The Union for International Cancer Control and the World Health Organization are prioritizing off-patent drugs in their efforts to facilitate oncology medicine access in developing nations.